nab-paclitaxel promising for Japanese NSCLC patients
Phase III trial results support the use of albumin-bound paclitaxel plus carboplatin as a first-line treatment for Japanese patients with advanced non-small-cell lung cancer. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - June 1, 2013 Category: Cancer & Oncology Source Type: news
Selective ALK inhibitor shows NSCLC promise
Preliminary trial results suggest that a novel, highly selective ALK inhibitor may be effective for the treatment of advanced non-small-cell lung cancer in Japanese patients with the ALK rearrangement. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - May 30, 2013 Category: Cancer & Oncology Source Type: news
Late radiotherapy ‘not inferior’ for patients
Researchers have questioned the timing of thoracic radiotherapy for patients undergoing four cycles of chemotherapy for limited-disease small-cell lung cancer. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - May 30, 2013 Category: Cancer & Oncology Source Type: news
Thalidomide fails to boost mesothelioma outcomes
Adding maintenance thalidomide to standard first-line chemotherapy does not improve outcomes among patients with malignant pleural or peritoneal mesothelioma, study findings indicate. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - May 10, 2013 Category: Cancer & Oncology Source Type: news
Burden of symptoms could guide NSCLC pemetrexed use
Symptom burden and performance status may help identify the patients with non-squamous non-small-cell lung cancer who are likely to respond to maintenance pemetrexed therapy, phase III trial findings suggest. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - May 8, 2013 Category: Cancer & Oncology Source Type: news
KRAS oncogene substitutions may be predictive in lung adenocarcinoma
Researchers have found that certain KRAS oncogene substitutions may have predictive value in lung adenocarcinoma. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - May 8, 2013 Category: Cancer & Oncology Source Type: news
TKI resistance markers found for NSCLC patients
Korean scientists have identified several genetic markers that may explain lack of response to tyrosine kinase inhibitor therapy in patients with epidermal growth factor receptor-activating, non-small-cell lung cancer. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - May 8, 2013 Category: Cancer & Oncology Source Type: news
Hsp90 inhibitor shows NSCLC promise
Treatment with a heatshock protein 90 inhibitor may induce loss of EML4-AKL expression in non-small cell lung cancer cells, preliminary results suggest. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - May 8, 2013 Category: Cancer & Oncology Source Type: news
Gene fusion reduces NSCLC patient survival
ROS1 fusions predict a poor outcome in Chinese patients with non-small-cell lung cancer, study findings suggest. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - May 8, 2013 Category: Cancer & Oncology Source Type: news
S-1 combination regimen effective for NSCLC
Researchers suggest that combined therapy with the fluoropyrimidine S-1, carboplatin, and bevacizumab followed by maintenance therapy with S-1 and bevacizumab should be first-line treatment for patients with advanced non-squamous non-small-cell lung cancer. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - May 8, 2013 Category: Cancer & Oncology Source Type: news
Potential interstitial lung disease markers identified
Study findings suggest that three proteins may be associated with interstitial lung disease development. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - April 26, 2013 Category: Cancer & Oncology Source Type: news
Erlotinib may improve life quality in advanced NSCLC
Treating advanced epidermal growth factor receptor-mutation-positive non-small-cell lung cancer with erlotinib appears to improve quality of life compared with standard first-line chemotherapy, study results indicate. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - April 2, 2013 Category: Cancer & Oncology Source Type: news
Modified prediction model may improve lung cancer detection
A modified lung cancer prediction model that includes risk factors identified in the National Lung Screening Trial may boost the accuracy with which 6-year lung cancer risk can be predicted, researchers report. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - April 2, 2013 Category: Cancer & Oncology Source Type: news
Erlotinib may improve life quality in advanced NSCLC
Treating advanced epidermal growth factor receptor-mutation-positive non-small-cell lung cancer with erlotinib appears to improve quality of life compared with standard first-line chemotherapy, study results indicate. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - April 2, 2013 Category: Cancer & Oncology Source Type: news
